The clinical performance is complex and often involves multi-system fatigue. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of MDS-related prognosis requires individualized management, typically including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many of the blood tumor diseases that were previously difficult to treat have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of EB1 proliferation of stem cells associated with MDS. The platform serves a team of internationally authoritative experts in the field of blood tumours in China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.